Showing results (861-870 of 1,524) with videos related to
Sort By:
Pageof 153
CPT: Pharmacometrics & Systems Pharmacology|May 18, 2022
Modeling the bacterial dynamics in the gut microbiota following an antibiotic-induced perturbationJinju Guk, Antoine Bridier-Nahmias, Mélanie Magnan, et al.CPT: Pharmacometrics & Systems Pharmacology|June 29, 2021
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myelomaKimiko Koiwai, Raouf El-Cheikh, Hoai-Thu Thai, et al.CPT: Pharmacometrics & Systems Pharmacology|December 7, 2018
Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus InhibitionPeng Duan, Fang Wu, Jason N Moore, et al.CPT: Pharmacometrics & Systems Pharmacology|March 24, 2018
Many Flavors of Model-Based Meta-Analysis: Part II - Modeling Summary Level Longitudinal ResponsesMartin Boucher, Meg BennettsCPT: Pharmacometrics & Systems Pharmacology|December 15, 2018
Models and Machines: How Deep Learning Will Take Clinical Pharmacology to the Next LevelLucy Hutchinson, Bernhard Steiert, Antoine Soubret, et al.CPT: Pharmacometrics & Systems Pharmacology|May 22, 2022
Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patientsJaydeep K Srimani, Paul M Diderichsen, Michael J Hanley, et al.CPT: Pharmacometrics & Systems Pharmacology|June 20, 2022
Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interactionLuna Prieto Garcia, Anna Lundahl, Christine Ahlström, et al.CPT: Pharmacometrics & Systems Pharmacology|June 21, 2022
Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatmentMélanie Wilbaux, David Demanse, Yi Gu, et al.CPT: Pharmacometrics & Systems Pharmacology|June 16, 2022
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseasesWannee Kantasiripitak, An Outtier, Sebastian G Wicha, et al.CPT: Pharmacometrics & Systems Pharmacology|June 4, 2021
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patientsStefan Willmann, Eleonora Marostica, Nelleke Snelder, et al.Pageof 153